News

Related Contributions

GSK open source compound hits model
GSK and Online Communities Create Unique Alliance to Stimulate Open Source Drug Discovery for Malaria
Brian K. Fiske, The Michael J. Fox Foundation for Parkinson's Research
01 Jun 2010
I thought this was an interesting approach that GSK has taken in releasing so much compound hit/structure data. Although in this case for compounds that target a malaria parasite, I wonder if similar ... 
New statin concerns a problem for PD therapeutic efforts?
Cholesterol drug side effects need watching: study
Brian K. Fiske, The Michael J. Fox Foundation for Parkinson's Research
21 May 2010
The recent news that statins may cause a variety of side effects (such as liver and kidney problem, cataracts and myopathy) makes me wonder how the PD field should proceed in its interest in statins ... 
Conformational change screening and research platform available to collaborators
Open Forum: for rapid-fire posting of your questions and comments.
Joshua Salafsky, Biodesy
08 Apr 2010
Are you interested in developing conformation-targeted therapeutics but are stymied by the assay? ... 
Key research priorities in 2010
Parkinson's Disease Society Announces 2010 Innovation Grants
Claire J Bale, Parkinson's UK, et al.
11 Jan 2010
Parkinson's UK (the Parkinson’s Disease Society) is the largest charity funder of Parkinson’s research in the UK. To date, we have invested over £45million into pioneering research. ... 
Pharmacokinetics and bioactivity of GDNF and NTN infused into the rat brain
Piotr Hadaczek, UCSF
19 Feb 2010
 ... 
Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain
Piotr Hadaczek, UCSF
09 Feb 2010
Our paper "Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain" has just been accepted for publication in Neuropharmacology. It ... 
Responses: 1
Navigating the Treacherous Waters of Translational Research
Jamie L Eberling, The Michael J. Fox Foundation for Parkinson's Research
11 Nov 2009
This is a critical time for the futures of both neurotrophic factor therapy and gene therapy for PD.  Controversy and challenges lie ahead and the fate of both of these approaches, or the ... 
When is a target validated?
Mark Frasier, The Michael J. Fox Foundation for Parkinson's Research
18 Sep 2009
I am interested in the last bullet point raised from the MJFF meeting. It is an interesting question related to the MJFF  Target Validation program. MJFF has funded work on several intriguing ... 
Clinical Trials for Presymptomatic PD patients?
Open Forum: for rapid-fire posting of your questions and comments.
Jamie L Eberling, The Michael J. Fox Foundation for Parkinson's Research
23 Mar 2010
Alzforum recently reported on the Alzheimer's Preventative Initiative (API), an effort led by Eric Reiman and Pierre Tariot to begin biomarker-driven drug trials in subjects who are at the highest ... 
Lessons from Dimebon
Open Forum: for rapid-fire posting of your questions and comments.
Shehan De Silva, The Michael J. Fox Foundation for Parkinson's Research
17 Mar 2010
This month, one of the best potential hopes for treating Alzheimer’s disease failed in its first late-stage clinical trial. As a result of a 2008 study, Dimebon, an antihistamine drug approved ...